{
  "id": "PK_UGT1A1_INHIB",
  "name": "UGT1A1 inhibition can increase exposure of UGT1A1 substrates",
  "domain": "PK",
  "severity": "major",
  "rule_class": "adjust_monitor",
  "tags": ["exposure_increase"],
  "actions": [
    "Consider alternatives to the inhibitor when feasible (educational).",
    "If used together, monitor for dose-related adverse effects of the affected drug."
  ],
  "logic": {
    "enzyme": {
      "id": "UGT1A1",
      "A_role": "substrate",
      "B_role": "inhibitor",
      "B_strength_in": ["moderate", "strong"]
    },
    "rationale": [
      "{B_name} inhibits {enzyme_id}, reducing glucuronidation clearance of {A_name}.",
      "Reduced Phase II metabolism can increase {A_name} exposure."
    ]
  },
  "explanation_template": "{B_name} inhibits UGT1A1 and {A_name} relies on UGT1A1 metabolism. This can increase {A_name} exposure and raise the risk of dose-related adverse effects.",
  "references": [
    {
      "source": "Educational note",
      "citation": "Mechanistic pattern: enzyme inhibition of UGT pathway can increase exposure of substrates."
    }
  ]
}
